Immunomedics, Inc. (IMMU): Commentary News

IMMU – Volatility in the shares as company is expected to release breast cancer data later today at a San Francisco Symposium.


Key Facts Surrounding This News Item


  • IMMU had a POWR Rating of D (Sell) coming into today.
  • IMMU was -14.40% below its 10-Day Moving Average coming into today.
  • IMMU was -16.37% below its 20-Day Moving Average coming into today.
  • IMMU was -20.58% below its 50-Day Moving Average coming into today.
  • IMMU was -15.20% below its 100-Day Moving Average coming into today.
  • IMMU was 3.15% above its 200-Day Moving Average coming into today.
  • IMMU had returned +146.19% year-to-date leading up to today’s news, versus a +19.42% return from the benchmark S&P 500 during the same period.

More Info About Immunomedics, Inc. (IMMU)


Immunomedics, Inc. focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases. The company was founded in 1982 and is based in Morris Plains, New Jersey. View our full IMMU ticker page with ratings, news, and more.

IMMU at a Glance

IMMU Current POWR Rating™
Overall POWR Rating™
IMMU Current Price $12.11 0.08%
More IMMU Ratings, Data, and News

IMMU Price Reaction

The day of this event (Dec. 6, 2017)
IMMU Closing Price$10.21 13.00%
IMMU Volume13,739,000
366.97% from avg
Leading up to this event
IMMU 1-mo return14.60%
After this event
IMMU 1-day return23.82%
IMMU 3-day return26.84%
IMMU 5-day return25.39%

IMMU Price Chart



More Immunomedics, Inc. (IMMU) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All IMMU News
Page generated in 0.8049 seconds.